<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740217</url>
  </required_header>
  <id_info>
    <org_study_id>GSN000299</org_study_id>
    <nct_id>NCT03740217</nct_id>
  </id_info>
  <brief_title>Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets</brief_title>
  <official_title>Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets and Evaluation of the Potential Impact of Concomitant Food Intake on the Relative Bioavailability of GKT137831 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genkyotex SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eurofins Optimed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>York Bioanalytical Solution</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genkyotex SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a comparative oral bioavailability study between GKT137831 capsules and
      tablets, together with an assessment of the impact of concomitant food intake on the relative
      bioavailability of GKT137831 tablets.

      This will be a randomized three-way open cross-over study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Actual">February 6, 2019</completion_date>
  <primary_completion_date type="Actual">February 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subject will be randomly allocated with different formulations of treatment or conditions (Fasting or Fed) during three periods (P1, P2 and P3).</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral bioavailability (Fz)</measure>
    <time_frame>72 hours</time_frame>
    <description>To compare the relative oral bioavailability GKT137831 formulated in capsules or in tablets in healthy male subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Food effect on Oral bioavailability (Fz)</measure>
    <time_frame>72 hours</time_frame>
    <description>To assess the impact of concomitant food intake on the relative bioavailability of GKT137831 after single oral dose administration of a 400 mg GKT137831 tablet in healthy male subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>7 days</time_frame>
    <description>To compare the safety and tolerability of single oral dose administration of 400 mg GKT137831 formulated in capsules or in tablets, and to evaluate the potential impact of concomitant food intake on the safety and tolerability of single oral dose administration of 400 mg GKT137831 tablet in healthy adult male subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral bioavailability of GKT138184</measure>
    <time_frame>72 hours</time_frame>
    <description>To compare the relative oral bioavailability GKT138184 after oral administration of GKT137831 formulated in capsules or in tablets in healthy male subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect on oral bioavailability of GKT138184</measure>
    <time_frame>72 hours</time_frame>
    <description>To assess the impact of concomitant food intake on the relative bioavailability of GKT138184 after single oral dose administration of a 400 mg GKT137831 tablet in healthy male subjects.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Phase 1</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single oral dose of 400 mg GKT137831 administered as 4 x 100 mg capsules in fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B:</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GKT137831</intervention_name>
    <description>oral bioavailable small molecule that selectively inhibit NOX1 and NOX4</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B:</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>NOX1/4 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subject, aged 18 to 60 years inclusive;

          2. Non-smoker subject or smoker of not more than 5 cigarettes a day ;

          3. No history of alcohol or drug abuse

          4. Body Mass Index (BMI) between 18 and 27 5 kg/m2 inclusive;

          5. Considered as healthy after a comprehensive clinical assessment (detailed medical
             history and complete physical examination);

          6. Signing a written informed consent prior to selection;

        Exclusion Criteria:

          1. Blood donation (including in the frame of a clinical study) within 2 months before
             administration;

          2. General anaesthesia within 3 months before administration;

          3. Presence or history of drug hypersensitivity, or allergic disease diagnosed and
             treated by a physician;

          4. Inability to abstain from intensive muscular effort;

          5. No possibility of contact in case of emergency;

          6. Any drug intake (except paracetamol) during the last month prior to the first
             administration;

          7. History or presence of drug or alcohol abuse (alcohol consumption &gt; 40 grams / day);

          8. Excessive consumption of beverages with xanthine bases (&gt; 4 cups or glasses / day);

          9. Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody,
             or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests;

         10. Positive results of screening for drugs of abuse;

         11. Subject who, in the judgment of the Investigator, is likely to be non-compliant or
             uncooperative during the study, or unable to cooperate because of a language problem,
             poor mental development;

         12. Exclusion period of a previous study;

         13. Administrative or legal supervision;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves DONAZZOLO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eurofins Optimed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gi√®res</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

